Journal: eLife

Article Title: Human-specific ARHGAP11B induces hallmarks of neocortical expansion in developing ferret neocortex

doi: 10.7554/eLife.41241

Figure Lengend Snippet: ( A ) Scheme of ferret neocortex development and experimental approach. ARHGAP11B was expressed in developing ferret neocortex by in utero electroporation at E33, when the OSVZ begins to form. Analyses were performed at E37, E40/P0, P10 and P16. Analysis of cortical progenitors was performed at E40/P0, analysis of post-mitotic cells at E40/P0, P10 and P16, and analysis of brain size and neocortex morphology at P16. ( B–D ) mRNA expression analysis by RT-qPCR at E37, P0, P10 and P16. RNA was isolated from cryosections of paraformaldehyde-fixed brain tissue following ferret in utero electroporation at E33. Expression of the housekeeping gene Hprt1 (B, note the lack of signal in the absence of reverse transcriptase (–RT)) was used for normalization of ARHGAP11B expression detected with two different primer pairs (C, ARHGAP11B_1 ; D, ARHGAP11B_2 ). Two control (Con_1, Con_2; white) and two ARHGAP11B-electroporated (11B_1, 11B_2; black) embryos were analyzed at each stage, except for P0 when one control and one ARHGAP11B-electroporated embryo were analyzed. Error bars represent SD of three PCR amplifications. ( E, F ) ARHGAP11B protein expression analysis by immunofluorescence. Ferret E33 neocortex was electroporated in utero with a plasmid encoding FP together with either a plasmid encoding ARHGAP11B or empty vector (Control), followed by analysis at E37. ( E ) Triple immunofluorescence for FP (green), ARHGAB11B (11B, magenta) and Arhgap11a (11a, yellow), combined with DAPI staining (white). Arrows, an ARHGAP11B+ FP+ cell that is Arhgap11a–; arrowheads, an Arhgap11a+ cell that is FP– ARHGAP11B–. Note that the exposure of images of ARHGAP11B staining in the control neocortex was longer than in the ARHGAP11B-electroporated neocortex, in order to show the lack of a specific signal in the control, where only unspecific signal at blood vessels was detected (asterisks). Images are single optical sections. Scale bars, 50 μm. ( F ) Triple immunofluorescence for FP (green), ARHGAB11B (11B, magenta) and Ki67 (yellow), combined with DAPI staining (white), upon electroporation of a plasmid encoding FP and a plasmid encoding ARHGAP11B. Images are single optical sections. Scale bar, 20 μm. Boxes (25 μm wide), indicating an ARHGAP11B-expressing BP (upper box) and an ARHGAP11B-expressing AP (lower box), are shown at higher magnification on the right. Dashed lines, cell bodies.

Article Snippet: Antibody , Rabbit polyclonal anti- Arhgap11A , Abcam , ab113261, RRID: AB_ 10866587 , (1:500).

Techniques: In Utero, Electroporation, Expressing, Quantitative RT-PCR, Isolation, Immunofluorescence, Plasmid Preparation, Staining

Journal: eLife

Article Title: Human-specific ARHGAP11B induces hallmarks of neocortical expansion in developing ferret neocortex

doi: 10.7554/eLife.41241

Figure Lengend Snippet:

Article Snippet: Antibody , Rabbit polyclonal anti- Arhgap11A , Abcam , ab113261, RRID: AB_ 10866587 , (1:500).

Techniques: Isolation, Staining, In Situ, TUNEL Assay, Imaging, Sequencing, Recombinant, Software

Journal: Cureus

Article Title: Expression of Leukemia Inhibitory Factor (LIF) and p53 on Human Fetal Lung After Chorioamnionitis Suffering

doi: 10.7759/cureus.76246

Figure Lengend Snippet: Comparison of LIF and p53 staining (negative, mild, moderate, strong) in each stage (pseudoglandular, canalicular, saccular). Statistically significant differences (p-value <0.05) are marked in bold. The result is significant at p < 0.05 (two-tailed hypothesis). LIF: leukemia inhibitory factor.

Article Snippet: The antibodies that were used were LIF (rabbit polyclonal ATLAS; Atlas Antibodies AB, Stockholm, Sweden) and p53 (monoclonal DO-7, DAKO; Agilent Technologies is located in: Santa Clara, California, USA).

Techniques: Comparison, Staining

Journal: Genes & Diseases

Article Title: Targeting LIF/LIFR signaling in cancer

doi: 10.1016/j.gendis.2021.04.003

Figure Lengend Snippet: Schematic depicting the drugs that inhibit LIF/LIFR downstream signaling. Anti LIF antibody MSC-1 or LIFR inhibitor EC359 can be used to directly interfere LIF/LIFR signaling. Targeting LIF/LIFR signaling using inhibitors of LIFR activated pathways including Jak1/STAT3 inhibitors, PI3K inhibitors or BRD inhibitors may also be useful to interfere LIF/LIFR signaling.

Article Snippet: Considering the importance of the LIF/LIFR pathway, Northern Biologics/Celgene recently developed a humanized Anti-LIF antibody (MSC-1) that blocks LIF signaling, and its utility is being tested in a phase I clinical trial to determine its safety and tolerability (ClinicalTrials.gov, NCT03490669 ).

Techniques: